You are here: Industry Insights > SEC

News List

IVERIC bio Announces Proposed Offering of Common Stock firstwordpharma
July 13, 2021
IVERIC bio, Inc. (Nasdaq: ISEE) (the "Company"), today announced that it is commencing an underwritten public offering of shares of its common stock.
Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
July 02, 2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the closing of an underwritten public offering of 3,565,000 shares of its common stock at a public offering price of $48.50 per share.
Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
July 01, 2021
Graphite Bio, Inc. today announced the closing of its previously announced initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share on June 29, 2021.
PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK firstwordpharma
June 30, 2021
Panbela Therapeutics, Inc. today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock.
ACURX PHARMACEUTICALS Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES firstwordpharma
June 30, 2021
Acurx announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares.
Intellia Therapeutics Announces Proposed Public Offering of Common Stock firstwordpharma
June 29, 2021
Intellia announced today that it has commenced an underwritten public offering of $400 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) .
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock firstwordpharma
June 29, 2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the commencement of a proposed underwritten public offering of $150 million of shares of its common stock.
Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 firstwordpharma
June 18, 2021
Harrow Health, Inc. an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior notes due 2026 (the "Notes")
Aclaris Announces Proposed Public Offering of Common Stock firstwordpharma
June 09, 2021
Aclaris Therapeutics, Inc.,today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering.
SEC recommends phase II/III clinical trials of Covaxin on 2-18 year-olds expresspharma
May 13, 2021
The trial will be conducted on 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

Previous page 1 2 3 4 5 Next page